Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE Policy document

LAST REVIEWED 2020-02-29

DATE 2015-02-28

TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C–2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE
Parliamentary submission

DATE
2014-10-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11519

POLICY TYPE  Parliamentary submission
DATE          2015-05-14
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs

Documents

Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
Canadian Medical Association

Page 1 of 2

Association Medecins

Canadian Medical Association
Bill C-17 An Act to amend the Food and Drugs Act

https://policybase.cma.ca/link/policy11196

POLICY TYPE
Parliamentary submission

DATE
2014-06-11

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

<table>
<thead>
<tr>
<th>POLICY TYPE</th>
<th>Parliamentary submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATE</td>
<td>2017-08-18</td>
</tr>
<tr>
<td>TOPICS</td>
<td>Pharmaceuticals, prescribing, cannabis, drugs</td>
</tr>
</tbody>
</table>

**Documents**

![CMA Submission: Bill C-45: The Cannabis Act](image)
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

POLICY TYPE: Parliamentary submission
DATE: 2018-04-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada's lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE: Policy endorsement
DATE: 2017-05-26
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Canadian Medical Association submission to the Standing Senate Committee on Banking, Trade and Commerce: Higher rate now: Why excise tax on tobacco is long overdue for an increase
https://policybase.cma.ca/link/policy11129

POLICY TYPE                Parliamentary submission
DATE                      2014-05-15
TOPICS                     Health care and patient safety
                            Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes

CMA POLICY

Cannabis for Medical Purposes

Cannabis is a complex and versatile plant that has been used for centuries for its therapeutic properties. The plant contains a variety of compounds, including cannabinoids, which are responsible for its effects on the human body. The use of cannabis for medical purposes has gained increasing attention in recent years, driven by advances in science and growing evidence of its potential benefits.

Policy

The Canadian Medical Association (CMA) recognizes the unique properties of cannabis and its potential for medical use. The CMA supports the use of cannabis for medical purposes, provided it is used under appropriate medical supervision and in accordance with established guidelines.

Guidelines

The CMA recommends that cannabis be used under the guidance of a healthcare provider familiar with its effects and appropriate dosages. The use of cannabis for medical purposes should be documented and monitored to ensure safety and effectiveness.

Regulatory Framework

The CMA supports the development of a comprehensive regulatory framework for cannabis that ensures its safe and effective use. This framework should include clear guidelines for the prescription, dispensing, and use of cannabis.

Conclusion

The CMA encourages healthcare providers to consider the use of cannabis for medical purposes, providing they are familiar with its effects and are able to monitor its use effectively. The development of evidence-based guidelines and a robust regulatory framework is essential to ensure the safe and effective use of cannabis for medical purposes.
CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
CMA Response: Health Canada’s Medical Marijuana Regulatory Proposal
https://policybase.cma.ca/link/policy10702

POLICY TYPE
Parliamentary submission

DATE
2013-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE  Response to consultation
DATE        2017-06-28
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA's Recommendations for Bill S-5: An Act to amend the Tobacco Act and
CMA Policybase - Canadian Medical Association
p. 12
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE
Parliamentary submission

DATE
2017-04-07

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13918

**POLICY TYPE**
Parliamentary submission

**DATE**
2018-02-15

**TOPICS**
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

**Documents**

CMA Submission:
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

Submission to the House of Commons Standing Committee on Health
February 15, 2018
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)

https://policybase.cma.ca/link/policy11599

POLICY TYPE: Response to consultation
DATE: 2015-06-08
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/link/policy11125

POLICY TYPE
Parliamentary submission

DATE
2014-03-26

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology – Prescription Pharmaceuticals in Canada: The Post-Approval Monitoring of Prescription Pharmaceuticals

https://policybase.cma.ca/link/policy10631

POLICY TYPE  Parliamentary submission
DATE  2012-10-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37

https://policybase.cma.ca/link/policy13617

POLICY TYPE
Parliamentary submission

DATE
2017-04-06

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission to the study of Bill C-37
An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts

Submission to the Senate Standing Committee on Legal and Constitutional Affairs

April 5, 2017